Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) has revealed that its ZokinvyTM (lonafarnib) has got permission from the FDA for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL). These syndromes double the death rate in young patients.
Eiger BioPharmaceuticals revealed that Zokinvy is confirmed to be very useful in improving the survival rate in children and young adults. Progeria patients who underwent Zokinvy treatment have shown positive results. Zokinvy lessened the rate of death by 60% and extended the average endurance time by 2.5 years.